STAMBPL1 depletion was found to induce apoptosis by promoting the degradation of the protein XIAP, suggesting that targeting STAMBPL1 might offer a promising therapeutic strategy for prostate cancer [23]. This evidence concerns the gene XIAP and prostate carcinoma.